^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    BTG2 (BTG Anti-Proliferation Factor 2)

    i
    Other names: BTG2, BTG Anti-Proliferation Factor 2, PC3, NGF-Inducible Anti-Proliferative Protein PC3, BTG Family Member 2, TIS21, APRO1, Nerve Growth Factor-Inducible Anti-Proliferative, B-Cell Translocation Gene 2, Pheochromacytoma Cell-3, Protein BTG2, MGC126063, MGC126064, BTG Family, Member 2
    Associations

    News

    Trials
    14d
    MicroRNA profiling identifies VHL/HIF-2α dependent miR-2355-5p as a key modulator of clear cell Renal cell carcinoma tumor growth. (PubMed, Cancer Cell Int)
    All five genes were significantly downregulated in ccRCC tumors and mouse xenograft tumors. The results from this research demonstrate the oncogenic ability of miR-2355-5p and shed light on the possible mechanism by which this miRNA controls angiogenesis and tumor growth in VHL-deficient ccRCC.
    Journal
    |
    VHL (von Hippel-Lindau tumor suppressor) • EPAS1 (Endothelial PAS domain protein 1) • CMTM4 (CKLF Like MARVEL Transmembrane Domain Containing 4) • SLIT2 (Slit Guidance Ligand 2) • ACO1 (Aconitase 1) • BTG2 (BTG Anti-Proliferation Factor 2)
    19d
    Linggui Zhugan decoction ameliorating mitochondrial damage of doxorubicin-induced cardiotoxicity by modulating the AMPK-FOXO3a pathway targeting BTG2. (PubMed, Phytomedicine)
    LGZGD exerts significant cardioprotective effects against DIC by reducing oxidative stress, inflammation, and apoptosis preserving while mitochondrial structure and function. These findings offer a novel insight into LGZGD's clinical relevance in DIC management. Targeting BTG2 to regulate the AMPK-FOXO3a pathway highlights LGZGD as a promising therapeutic strategy for preventing and treating DIC.
    Journal
    |
    BTG2 (BTG Anti-Proliferation Factor 2)
    |
    doxorubicin hydrochloride
    1m
    LncRNA PVT1 links estrogen receptor alpha and the polycomb repressive complex 2 in suppression of pro-apoptotic genes in hormone-responsive breast cancer. (PubMed, Cell Death Dis)
    Functional assays and transcriptome analysis following lncRNA knock-down indicated PVT1 as the master modulator of some of the most relevant BC hallmarks, such as cell proliferation, apoptosis, migration and response to hypoxia. In addition, targeted experiments identified PVT1 as a key factor in the composition of PRC2-ERα network involved in downregulation of tumor suppressor genes, including BTG2.
    Journal
    |
    ER (Estrogen receptor) • PVT1 (Pvt1 Oncogene) • BTG2 (BTG Anti-Proliferation Factor 2) • FGD5-AS1 (FGD5 Antisense RNA 1)
    1m
    High-dose methotrexate, ibrutinib, and temozolomide in the treatment of newly diagnosed primary CNS lymphoma: a multicenter, prospective phase-II study. (PubMed, Blood Cancer Discov)
    The consistency of ctDNA clearance from CSF/plasma and complete response on imaging were observed. Patients with clearance of ctDNA from CSF after two cycles achieved longer PFS (p = 0.044).
    P2 data • Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD79B (CD79b Molecule) • PIM1 (Pim-1 Proto-Oncogene) • BTG2 (BTG Anti-Proliferation Factor 2)
    |
    Imbruvica (ibrutinib) • temozolomide • methotrexate • methotrexate IV
    2ms
    Metabolic-Immune Suppression Mediated by the SIRT1-CX3CL1 Axis Induces Functional Enhancement of Regulatory T Cells in Colorectal Carcinoma. (PubMed, Adv Sci (Weinh))
    Additionally, the therapeutic efficacy of CX3CR1 inhibitor monotherapy and combination therapy is validated with the PD-1 antibody in the humanized subcutaneous CRC mouse model. This study elucidates a potential mechanism that metabolic reprogramming of cancer cells collaborates with subsequent immunosuppression to promote CRC progression.
    Journal
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9) • CX3CL1 (C-X3-C Motif Chemokine Ligand 1) • SATB1 (SATB Homeobox 1) • SIRT1 (Sirtuin 1) • BTG2 (BTG Anti-Proliferation Factor 2) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1) • TCF7 (Transcription Factor 7)
    3ms
    Four functional genotoxic marker genes (Bax, Btg2, Ccng1, and Cdkn1a) discriminate genotoxic hepatocarcinogens from non-genotoxic hepatocarcinogens and non-genotoxic non-hepatocarcinogens in rat public toxicogenomics data, Open TG-GATEs. (PubMed, Genes Environ)
    The present results unequivocally demonstrate the availability of four genotoxic marker genes ((Bax, Btg2, Ccng1, and Cdkn1a) and PCA in discriminating GTHCs from NGTHCs and NGTNHCs in Open TG-GATEs. These findings strongly support our recommendation that future rat liver in vivo toxicogenomics tests prioritize these four genotoxic marker genes, as they have proven to be highly effective in discriminating between different types of hepatocarcinogens.
    Preclinical • Journal
    |
    GDF15 (Growth differentiation factor 15) • BAX (BCL2-associated X protein) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • LRP1 (LDL Receptor Related Protein 1) • PLK2 (Polo Like Kinase 2) • BTG2 (BTG Anti-Proliferation Factor 2) • CCNF (Cyclin F) • CCNG1 (Cyclin G1)
    |
    dexamethasone • aspirin
    3ms
    The roles of LncRNA CARMN in cancers: biomarker potential, therapeutic targeting, and immune response. (PubMed, Discov Oncol)
    This review emphasizes the diverse roles of CARMN across different cancers and its potential as a diagnostic and therapeutic tool. Future research should address the mechanistic details of CARMN's involvement in cancer, validate its clinical utility, and explore its therapeutic potential in combination with existing treatments.
    Review • Journal
    |
    TP53 (Tumor protein P53) • MMP2 (Matrix metallopeptidase 2) • FGF2 (Fibroblast Growth Factor 2) • BTG2 (BTG Anti-Proliferation Factor 2) • DHX9 (DExH-Box Helicase 9)
    |
    TP53 mutation
    3ms
    LncRNA MIR600HG inhibits laryngeal cancer development by mediating the miR-424-5p/BTG2 axis. (PubMed, Cancer Sci)
    In addition, overexpression of BTG2 inhibited laryngeal cancer progression, whereas MIR600HG knockdown or miR-424-5p overexpression reversed the role of BTG2. This work suggested that MIR600HG represses laryngeal tumor development by regulating the miR-424-5p/BTG2 axis, which provides new molecules for early diagnosis of laryngeal cancer in the future.
    Journal
    |
    MIR424 (MicroRNA 424) • BTG2 (BTG Anti-Proliferation Factor 2)
    4ms
    The tumor suppressor SALL2 opposes chemotherapeutic resistance in breast cancer. (PubMed, Mol Cell Biochem)
    This resistance was mediated, at least in part, through the transcriptional regulation of BTG2, a negative regulator of stemness, achieved by direct binding to its promoter regions. These findings underscore the critical role of SALL2 in modulating cisplatin response and propose SALL2 as a potential prognostic biomarker for chemotherapy response in breast cancer.
    Journal
    |
    BTG2 (BTG Anti-Proliferation Factor 2)
    |
    cisplatin
    4ms
    Putative mechanisms of primary resistance to EGFR-targeted therapies: A retrospective study. (PubMed, Lung Cancer)
    The genomic landscape varies significantly among patients with LUAD, which should be considered when making personalized treatment decisions. This information could provide insights into molecular changes and their effects on clinical treatment in diverse patients with LUAD harboring sensitizing EGFR mutations.
    Retrospective data • Journal
    |
    TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MUC16 (Mucin 16, Cell Surface Associated) • RBM10 (RNA Binding Motif Protein 10) • EPAS1 (Endothelial PAS domain protein 1) • BTG2 (BTG Anti-Proliferation Factor 2)
    |
    TP53 mutation • EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    4ms
    Analysis of Therapeutic Efficacy and Adverse Prognostic Factors of Secondary Central Nervous System Lymphoma (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
    HD-MTX combined with TMZ as the first-line strategy may improve patient prognosis, and early application of gene sequencing is beneficial for evaluating prognosis.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • KMT2D (Lysine Methyltransferase 2D) • CD79B (CD79b Molecule) • PIM1 (Pim-1 Proto-Oncogene) • BTG2 (BTG Anti-Proliferation Factor 2) • TBL1XR1 (TBL1X Receptor 1)
    |
    HER-2 mutation • PIM1 mutation
    |
    methotrexate IV
    5ms
    Efficacy and safety analysis of the OR-CHOP regimen for the treatment of MCD subtype diffuse large B cell lymphoma in the real-world setting (PubMed, Zhonghua Xue Ye Xue Za Zhi)
    Objective: To investigate the efficacy and safety of orelabrutinib combined with R-CHOP in the treatment of MCD subtype diffuse large B cell lymphoma (DLBCL)...All patients were treated with R-CHOP or R-miniCHOP in Course 1, OR-CHOP or OR-miniCHOP (21 days for one course) in Courses 2-6, and R-monotherapy in Courses 7-8...Furthermore, the OR-CHOP regimen was generally well tolerated during clinical use, with hematological toxicity being the main adverse effect. This study revealed that the OR-CHOP regimen can be used as an effective and safe first-line treatment for MCD subtype DLBCL.
    Retrospective data • Journal • Real-world evidence • Real-world
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • ETV6 (ETS Variant Transcription Factor 6) • KMT2D (Lysine Methyltransferase 2D) • CD79B (CD79b Molecule) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • PIM1 (Pim-1 Proto-Oncogene) • CD58 (CD58 Molecule) • H1-4 (H1.4 Linker Histone, Cluster Member) • BTG2 (BTG Anti-Proliferation Factor 2)
    |
    Rituxan (rituximab) • vincristine • Inokai (orelabrutinib)
    5ms
    The DHODH inhibitor teriflunomide impedes cell proliferation and enhances chemosensitivity to daunorubicin (DNR) in T-cell acute lymphoblastic leukemia. (PubMed, Ann Hematol)
    Moreover, combined treatment with TRF and daunorubicin (DNR) significantly reduced cell viability and promoted apoptosis in DNR-resistant T-ALL cells. Our study provides valuable insights into the critical role of TRF in treating T-ALL while increasing the sensitivity of DNR-resistant T-ALL cells to DNR.
    Journal
    |
    TP53 (Tumor protein P53) • BTG2 (BTG Anti-Proliferation Factor 2)
    |
    TP53 expression
    |
    daunorubicin
    8ms
    Transcriptomic Hallmarks of Hypoxic-Ischemic Brain Injury: Insights from an in Vitro Model. (PubMed, J Integr Neurosci)
    The present study provides a comprehensive transcriptomic profile of an in vitro OGD/R process. Key hub genes and pathways were identified, offering potential targets for neuroprotection after hypoxic ischemia.
    Preclinical • Journal
    |
    ER (Estrogen receptor) • TNFA (Tumor Necrosis Factor-Alpha) • SPP1 (Secreted Phosphoprotein 1) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • IGF1 (Insulin-like growth factor 1) • HMOX1 (Heme Oxygenase 1) • CCL2 (Chemokine (C-C motif) ligand 2) • IL17A (Interleukin 17A) • SERPINE1 (Serpin Family E Member 1) • TXNIP (Thioredoxin Interacting Protein) • ATF3 (Activating Transcription Factor 3) • BTG2 (BTG Anti-Proliferation Factor 2) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • EGR1 (Early Growth Response 1)
    8ms
    Circulating tumor DNA assisting lymphoma genetic feature profiling and identification. (PubMed, Ann Hematol)
    Lymphoma genomic profiling by ctDNA was concordant with that by tumor tissues. ctDNA might also be applied in lymphoma surveillance.
    Journal • PD(L)-1 Biomarker • IO biomarker • Circulating tumor DNA
    |
    PD-L1 (Programmed death ligand 1) • PD-L2 (Programmed Cell Death 1 Ligand 2) • PIM1 (Pim-1 Proto-Oncogene) • SOCS1 (Suppressor Of Cytokine Signaling 1) • STAT6 (Signal transducer and activator of transcription 6) • BTG2 (BTG Anti-Proliferation Factor 2)
    8ms
    Unraveling the noncoding RNA landscape in glioblastoma: from pathogenesis to precision therapeutics. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    Targeting oncogenic ncRNAs with RNA-interfering strategies such as MOs, ASOs, LNAs, CRISPR-Cas9 gene editing, and PNA approaches may represent a promising therapeutic strategy for GBM. This review emphasizes the critical role of ncRNAs in GBM pathogenesis, as well as the potential for new therapeutic strategies targeting these pathways to improve the prognosis and quality of life for GBM patients.
    Review • Journal
    |
    MIR155 (MicroRNA 155) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • MIR21 (MicroRNA 21) • HOTAIR (HOX Transcript Antisense RNA) • FOXO3 (Forkhead box O3) • MIR27A (MicroRNA 27a) • BCYRN1 (Brain Cytoplasmic RNA 1) • BTG2 (BTG Anti-Proliferation Factor 2) • MIR10B (MicroRNA 10b) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)
    8ms
    Targeting HTR2B suppresses non-functioning pituitary adenoma growth and sensitizes cabergoline treatment via inhibiting Gαq/PLC/PKCγ/STAT3 axis. (PubMed, Neuro Oncol)
    HTR2B is a potential therapeutic target for NFPAs, and its inhibition could improve CAB efficacy. A dual therapy approach may be beneficial for NFPA patients with high HTR2B expression.
    Journal
    |
    BTG2 (BTG Anti-Proliferation Factor 2) • HTR2B (5-Hydroxytryptamine Receptor 2B)
    8ms
    Merkel cell polyomavirus pan-T antigen knockdown reduces cancer cell stemness and promotes neural differentiation independent of RB1. (PubMed, J Med Virol)
    Moreover, spatially resolved transcriptomics demonstrated reduced TA expression in situ in a part of a MCC tumor characterized by neural differentiation. In summary, TAs are critical for maintaining stemness of MCC cells and suppressing neural differentiation, irrespective of their impact on the RB-signaling pathway.
    Journal
    |
    RB1 (RB Transcriptional Corepressor 1) • PBX1 (PBX Homeobox 1) • BTG2 (BTG Anti-Proliferation Factor 2) • E2F1 (E2F transcription factor 1) • E2F8 (E2F Transcription Factor 8)
    8ms
    Disease types and pathogenic mechanisms induced by PM2.5 in five human systems: An analysis using omics and human disease databases. (PubMed, Environ Int)
    This study provides a novel analysis strategy for elucidating PM2.5-related disease types and is an important supplement to epidemiological investigation. It clarifies the risks of PM2.5 exposure, elucidates the pathogenic mechanisms, and provides scientific support for promoting the precise prevention and treatment of PM2.5-related diseases.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BIRC5 (Baculoviral IAP repeat containing 5) • STAT1 (Signal Transducer And Activator Of Transcription 1) • BTG2 (BTG Anti-Proliferation Factor 2)
    10ms
    Delineating the mechanistic relevance of the TP53 gene and its mutational impact on gene expression and patients' survival in bladder cancer. (PubMed, Heliyon)
    The multivariate analysis highlighted the predictive power of TP53 mutations, with a high frequency of high-grade tumors (78.57 %) in mutated patients, underscoring their role in cancer progression. In conclusion, this study emphasizes the crucial role of TP53 mutations in bladder cancer patients from Bangladesh.
    Journal
    |
    TP53 (Tumor protein P53) • BTG2 (BTG Anti-Proliferation Factor 2)
    10ms
    A Brain Anti-Senescence Transcriptional Program Triggered by Hypothalamic-Derived Exosomal microRNAs. (PubMed, Int J Mol Sci)
    Furthermore, heterochronic parabiosis can reverse age-related upregulation of specific miRNA-targeted genes, predominantly in brain endothelial cells, including senescence promoting genes such as Cdkn1a and Btg2. Our findings support the presence of an anti-senescence mechanism triggered by the endocrine secretion of htNSC-derived exosomal miRNAs, which is associated with a youthful transcriptional signature.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • TXNIP (Thioredoxin Interacting Protein) • BTG2 (BTG Anti-Proliferation Factor 2)
    10ms
    Anchorage Dependence and Cancer Metastasis. (PubMed, J Korean Med Sci)
    Crucially, the suppression of AST substantially reduces metastasis while sparing primary tumors. These findings open up possibilities for developing targeted therapies that inhibit metastasis and emphasize the importance of AST, leading to a fundamental change in our comprehension of how cancer spreads.
    Review • Journal
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • IRF8 (Interferon Regulatory Factor 8) • BTG2 (BTG Anti-Proliferation Factor 2)
    10ms
    SMC2 knockdown inhibits malignant progression of lung adenocarcinoma by upregulating BTG2 expression. (PubMed, Cell Signal)
    Furthermore, SMC2 knockdown effectively prevented the formation of subcutaneous, intracranial and metastatic tumor in vivo, and upregulation of BTG2 expression after SMC2 knockdown was confirmed in tumor models. This study revealed that SMC2 knockdown restrained the malignant progression of LUAD through upregulation of BTG2 expression and inactivation of ERK and AKT pathway, and SMC2 could be a potential therapeutic target for LUAD treatment.
    Journal
    |
    TP53 (Tumor protein P53) • BTG2 (BTG Anti-Proliferation Factor 2)
    |
    TP53 expression
    11ms
    Elucidating the chain of command: our current understanding of critical target genes for p53-mediated tumor suppression. (PubMed, Crit Rev Biochem Mol Biol)
    These include ZMAT3, GLS2, PADI4, ZBXW7, RFX7, and BTG2. The findings from these studies provide a more complex, but exciting, potential framework for understanding the role of p53 in tumor suppression.
    Review • Journal
    |
    TP53 (Tumor protein P53) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • BBC3 (BCL2 Binding Component 3) • BTG2 (BTG Anti-Proliferation Factor 2) • ZMAT3 (Zinc Finger Matrin-Type 3)
    |
    TP53 mutation
    11ms
    Multi-endpoint in vitro toxicological assessment of snus and tobacco-free nicotine pouch extracts. (PubMed, Mutat Res Genet Toxicol Environ Mutagen)
    CRP 1.1 extracts resulted in the release of several inflammatory mediators including cytokines IL-1α, IL5, IL6, IL8, IL-1RA, MIF and TNF-β, receptor IL-2RA, and growth factors FGF-basic, VEGF and M-CSF. In conclusion these assays contribute to the weight of evidence assessment of the potential comparative health risks of NPs and snus.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL2RA (Interleukin 2 receptor, alpha) • CSF1 (Colony stimulating factor 1) • CREB1 (CAMP Responsive Element Binding Protein 1) • DDIT3 (DNA-damage-inducible transcript 3) • IL1R1 (Interleukin 1 receptor, type I) • IL5 (Interleukin 5) • AKT1S1 (AKT1 Substrate 1) • BTG2 (BTG Anti-Proliferation Factor 2)
    12ms
    Prognostic effect of DNA methylation of BTG2 gene in Chinese hepatocellular carcinoma. (PubMed, Heliyon)
    The prognostic efficiency of death risk score was superior to that of cirrhosis or microvascular invasion alone. The methylation level of cg01798157 in BTG2 may be an epigenetic biomarker in Chinese patients with resectable HCC.
    Journal • Epigenetic controller
    |
    BTG2 (BTG Anti-Proliferation Factor 2)
    12ms
    Exploring diverse programmed cell-death patterns to develop a novel gene signature for predicting the prognosis of lung adenocarcinoma patients. (PubMed, J Thorac Dis)
    This study identified a 9-gene signature (CDI) based on PCD-related genes that accurately predicted the prognosis of LUAD patients. The CDI could serve as a valuable prognostic indicator and guide personalized therapeutic strategies for LUAD.
    Journal • Gene Signature • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • CCNB2 (Cyclin B2) • BTG2 (BTG Anti-Proliferation Factor 2) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • PTGDS (Prostaglandin D2 Synthase)
    1year
    Mutational, immune microenvironment, and clinicopathological profiles of diffuse large B-cell lymphoma and follicular lymphoma with BCL6 rearrangement. (PubMed, Virchows Arch)
    In conclusion, both BCL6-R-positive FL and BCL6-R-positive DLBCL had a common mutational profile; but also, differences. DLBCL cases had a higher density of microenvironment markers.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BCL2 (B-cell CLL/lymphoma 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NOTCH1 (Notch 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • BCL6 (B-cell CLL/lymphoma 6) • KMT2D (Lysine Methyltransferase 2D) • NOTCH2 (Notch 2) • CREBBP (CREB binding protein) • CD163 (CD163 Molecule) • ARID1B (AT-Rich Interaction Domain 1B) • CD36 (thrombospondin receptor) • IL10 (Interleukin 10) • RHOA (Ras homolog family member A) • PIM1 (Pim-1 Proto-Oncogene) • CSF1R (Colony stimulating factor 1 receptor) • HLA-B (Major Histocompatibility Complex, Class I, B) • H1-4 (H1.4 Linker Histone, Cluster Member) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2) • BTG2 (BTG Anti-Proliferation Factor 2) • LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1)
    |
    ATM mutation • MYD88 L265P • BCL6 rearrangement • ARID1B mutation • IL10-L • PIM1 mutation • MYC negative
    1year
    DNA Copy Number Alterations and Copy Neutral Loss of Heterozygosity in Adult Ph-Negative Acute B-Lymphoblastic Leukemia: Focus on the Genes Involved. (PubMed, Int J Mol Sci)
    Of the 36 patients, only 5 (13.8%) had a normal molecular karyotype, and 31 (86.2%) were found to have various molecular karyotype abnormalities-104 deletions, 90 duplications or amplifications, 29 cases of cnLOH and 7 biallelic/homozygous deletions. We found that 11q22-23 duplication involving the BIRC3, ATM and MLL genes was the most adverse prognostic event in the study cohort.
    Journal
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR3 (Fibroblast growth factor receptor 3) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • NF1 (Neurofibromin 1) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6) • CRLF2 (Cytokine Receptor Like Factor 2) • IKZF1 (IKAROS Family Zinc Finger 1) • MAP2K2 (Mitogen-activated protein kinase kinase 2) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • BIRC3 (Baculoviral IAP repeat containing 3) • PAX5 (Paired Box 5) • ARID1B (AT-Rich Interaction Domain 1B) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • EP300 (E1A binding protein p300) • IKZF3 (IKAROS Family Zinc Finger 3) • CCL20 (C-C Motif Chemokine Ligand 20) • TCF3 (Transcription Factor 3) • CIP2A (Cellular Inhibitor Of PP2A) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • IKZF2 (IKAROS family zinc finger 2) • SH2B3 (SH2B Adaptor Protein 3) • XPA (XPA, DNA Damage Recognition And Repair Factor) • DOCK8 (Dedicator Of Cytokinesis 8) • MEF2C (Myocyte Enhancer Factor 2C) • MEF2D (Myocyte Enhancer Factor 2D) • SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2) • BTG2 (BTG Anti-Proliferation Factor 2) • PAX3 (Paired Box 3) • RAG1 (Recombination Activating 1) • RUNX2 (RUNX Family Transcription Factor 2) • ZNF384 (Zinc Finger Protein 384)
    over1year
    Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy (PubMed, Zhonghua Xue Ye Xue Za Zhi)
    ctDNA detection can serve as a tool for evaluating the efficacy of CAR-T-cell therapy in patients with R/R DLBCL. The pretreatment gene mutation burden, mutations in MUC16 and BTG2 have potential prognostic value.
    Journal • CAR T-Cell Therapy • Tumor mutational burden • IO biomarker • Circulating tumor DNA
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • KMT2D (Lysine Methyltransferase 2D) • KMT2C (Lysine Methyltransferase 2C) • MUC16 (Mucin 16, Cell Surface Associated) • TTN (Titin) • IGLL5 (Immunoglobulin Lambda Like Polypeptide 5) • BTG2 (BTG Anti-Proliferation Factor 2)
    |
    TP53 mutation • MUC16 mutation
    over1year
    A pan-cancer analysis of anti-proliferative protein family genes for therapeutic targets in cancer. (PubMed, Sci Rep)
    Finally, our study also demonstrated the relationship between APRO family genes and drug sensitivity. This study provides comprehensive information to understand the APRO family's role as an oncogene and predictor of survival in some tumor types.
    Journal • Tumor mutational burden • IO biomarker • Pan tumor
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • BTG2 (BTG Anti-Proliferation Factor 2)
    over1year
    miR-17-92 cluster-BTG2 axis regulates B-cell receptor signaling in mantle cell lymphoma. (PubMed, Cancer Sci)
    Our results suggest an oncogenic role of miR-17-92 cluster-activating BCR signaling throughout BTG2 deregulation in MCL. Furthermore, this may contribute to the prediction of the therapeutic efficacy and improved outcomes of MCL.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TET2 (Tet Methylcytosine Dioxygenase 2) • MIR17HG (MiR-17-92a-1 Cluster Host Gene) • TNFRSF10A (TNF Receptor Superfamily Member 10a) • MIR17 (MicroRNA 17) • MIR18A (MicroRNA 18a) • MIR19B1 (MicroRNA 19b-1) • MIR92A1 (MicroRNA 92a-1) • SOX11 (SRY-Box Transcription Factor 11) • SYNE1 (Spectrin Repeat Containing Nuclear Envelope Protein 1) • BTG2 (BTG Anti-Proliferation Factor 2) • MIR20A (MicroRNA 20a)
    |
    SOX11 expression
    over1year
    A Prospective, Exploratory, Phase II Study of the Xpo-1 Inhibitor Selinexor in Combination with RCHOP in Double/Triple-Hit Large B-Cell Lymphoma (ASH 2023)
    The optimal treatment for DH/TH lymphoma remains unclear, although outcomes are inadequate with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) alone...The initial dose of each drug in this regimen is as follows (repeat every 21 days, 6 cycles in total): rituximab: 375mg/m 2, d0; vindesine 4mg, d1; epirubicin 75mg/m 2, d1 (or liposomal doxubicin 35mg/m 2, d1); cyclophosphamide: 750mg/m 2, d1; prednisone: 100mg, d1-5; selinexor 60mg orally once a week...Dynamic testing of ctDNA demonstrated deep remission to chemotherapy. Based on the encouraging results of the current study, a large scale, multicenter trial is needed to further investigate this promising regimen.
    Clinical • P2 data • Combination therapy • IO biomarker
    |
    TP53 (Tumor protein P53) • BCL6 (B-cell CLL/lymphoma 6) • XPO1 (Exportin 1) • TNFRSF14 (TNF Receptor Superfamily Member 14) • SOCS1 (Suppressor Of Cytokine Signaling 1) • ETS1 (ETS Proto-Oncogene 1) • IGLL5 (Immunoglobulin Lambda Like Polypeptide 5) • NFKBIE (NFKB Inhibitor Epsilon) • BTG2 (BTG Anti-Proliferation Factor 2)
    |
    TP53 mutation • TNFRSF14 mutation
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Xpovio (selinexor) • epirubicin • vincristine • prednisone • vindesine
    over1year
    Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer. (PubMed, Genes (Basel))
    To reveal the mechanism of drug resistance, the molecular networks of anti-cancer drugs such as cisplatin, carboplatin, oxaliplatin, and arsenic trioxide were analyzed in several types of cancers...The upstream regulators of the molecular networks of cisplatin-treated lung adenocarcinoma included the anti-cancer drug trichostatin A (TSA), a histone deacetylase inhibitor...Analysis of oxaliplatin, a platinum drug, revealed that the SPINK1 pancreatic cancer pathway is inactivated in ischemic cardiomyopathy. The study showed the importance of the molecular networks of anti-cancer drugs and tumor microenvironment in the treatment of cancer resistant to anti-cancer drugs.
    Journal
    |
    CDKN1A (Cyclin-dependent kinase inhibitor 1A) • SESN1 (Sestrin 1) • SPINK1 (Serine peptidase inhibitor, kazal type 1) • BTG2 (BTG Anti-Proliferation Factor 2)
    |
    cisplatin • carboplatin • oxaliplatin • arsenic trioxide • trichostatin A (VTR-297)
    over1year
    Clonal Relationship and Mutation Analysis in Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Associated With Diffuse Large B-cell Lymphoma. (PubMed, Hemasphere)
    Together, we demonstrate variable clonal B-cell dynamics in LPL/WM patients developing DLBCL, and the occurrence of clonally unrelated DLBCL in about one-quarter of LPL/WM patients. Moreover, we identified commonly mutated genes upon DLBCL transformation, which together with preserved mutations already present in LPL characterize the mutational landscape of DLBCL occurrences in LPL/WM patients.
    Journal
    |
    TP53 (Tumor protein P53) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • CD79B (CD79b Molecule) • CARD11 (Caspase Recruitment Domain Family Member 11) • TNFAIP3 (TNF Alpha Induced Protein 3) • PIM1 (Pim-1 Proto-Oncogene) • BTG1 (BTG Anti-Proliferation Factor 1) • BTG2 (BTG Anti-Proliferation Factor 2)
    |
    TP53 mutation • MYD88 mutation • CXCR4 mutation • CD79B mutation • TNFAIP3 mutation • BTG1 mutation • CD79B mutation + TNFAIP3 mutation
    over1year
    The Effect of Gene Editing by CRISPR-Cas9 of miR-21 and the Indirect Target MMP9 in Metastatic Prostate Cancer. (PubMed, Int J Mol Sci)
    Reduced cell proliferation, increased apoptosis and low invasion in MMP9 and miR-21 edited cells was observed, compared to Scramble. CRISPR-Cas9-edited cells of miR-21 and MMP9 attenuate cell proliferation, invasion and stimulate apoptosis, impeding PCa evolution.
    Journal • Metastases
    |
    CDH1 (Cadherin 1) • MIR21 (MicroRNA 21) • MMP9 (Matrix metallopeptidase 9) • BTG2 (BTG Anti-Proliferation Factor 2) • ITGB1 (Integrin Subunit Beta 1) • MARCKS (Myristoylated Alanine Rich Protein Kinase C Substrate) • ITGB3 (Integrin Subunit Beta 3)
    over1year
    TL-895, a Highly Selective, Covalent Inhibitor of Bruton's Tyrosine Kinase (BTK), Sensitizes Myeloproliferative Neoplasm (MPN)-Blast Phase Stem Cells to Navtemadlin By Targeting Intrinsic Dysregulated MDM2/p53 and NF-Κb Pathways and Disrupting the Protective Tumor Microenvironment (TME) (ASH 2023)
    Our results indicate that BTKi therapy might increase susceptibility of MPN-BP SC to MDM2i therapy, by upregulating p53 activity and dampening NF-κB signaling, and also by disrupting protective TME interactions that sustain MPN-BP SC. This novel combination merits further clinical investigation in advanced phase MPN.
    IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • MDM2 (E3 ubiquitin protein ligase) • ETV6 (ETS Variant Transcription Factor 6) • BCL2L1 (BCL2-like 1) • WT1 (WT1 Transcription Factor) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1) • CDK1 (Cyclin-dependent kinase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • DDB2 (Damage Specific DNA Binding Protein 2) • ATF3 (Activating Transcription Factor 3) • BTG2 (BTG Anti-Proliferation Factor 2)
    |
    KRAS mutation • TP53 wild-type • WT1 mutation • ETV6 mutation
    |
    navtemadlin (KRT-232) • M7583
    over1year
    Clinical and Molecular Features of Patients with Double/Triple Hit Large B-Cell Lymphoma (ASH 2023)
    On the other hand, HGBL-DH/TH displays aggressive features, including a high incidence of advanced disease at diagnosis, and inferior efficacy to standard-induced chemical immunotherapy with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). DHL-BCL2/THL exhibits similar clinical characteristics, prognostic outcomes, and molecular features that set it apart from DHL-BCL6. This implies the need for testing novel agents or therapeutic strategies to expedite treatment development for patients with DHL-BCL2/THL.
    Clinical • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CREBBP (CREB binding protein) • CD70 (CD70 Molecule) • BTG2 (BTG Anti-Proliferation Factor 2)
    |
    BCL6 rearrangement • MYC translocation • BCL2 rearrangement • MYC translocation + BCL2 translocation • BCL6 translocation • MYC translocation + BCL6 translocation • BCL2 translocation
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone
    over1year
    High-Dose Methotrexate, Ibrutinib and Temozolomide (MIT) for the Treatment of Newly Diagnosed Primary Central Nervous System Lymphoma: A Multi-Center Prospective Phase II Study (ASH 2023)
    The novel induction treatment of MIT achieved encouraging responses in newly diagnosed PCNSL patients with acceptable toxicities. The early clearance of ctDNA in CSF may be related to favorable survival.
    Clinical • P2 data
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD79B (CD79b Molecule) • PIM1 (Pim-1 Proto-Oncogene) • BTG2 (BTG Anti-Proliferation Factor 2)
    |
    MYD88 mutation • PIM1 mutation
    |
    Imbruvica (ibrutinib) • temozolomide • methotrexate IV
    over1year
    BTG2 Super-Enhancer Mutations Disrupt TFAP4 Binding and Deregulate BTG2 Expression in Diffuse Large B-Cell Lymphoma (ASH 2023)
    The programs modulated by BTG2 and TFAP4 in the GC, and disrupted in tumors carrying deregulated BTG2 alleles, will be presented, as defined by RNA-seq analysis of 3 isogenic GC-derived cell lines followed by interrogation of over 100 clinically annotated primary DLBCL biopsies. Together, these data identify TFAP4 as a novel regulator of BTG2 and reveal a previously unappreciated mechanism by which mutations in the BTG2 SE disrupt this circuit and contribute to lymphomagenesis through deregulating BTG2 expression.
    IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • BTG2 (BTG Anti-Proliferation Factor 2)
    over1year
    Establishment of a Dynamic Ctdna Monitoring System to Predict the Prognosis of CAR-T Cell Therapy in R/R B-NHL Patients (ASH 2023)
    In this study, we evaluated the characteristics of gene mutation between different therapeutic groups, and a gene set was screened to predict the efficacy of CAR-T cell therapy in R/R B-NHL patients, helping clinicians accurately evaluate the efficacy and assisting in decision-making of treatment options.
    Clinical • CAR T-Cell Therapy • IO biomarker • Circulating tumor DNA
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • KMT2D (Lysine Methyltransferase 2D) • MUC16 (Mucin 16, Cell Surface Associated) • FAT1 (FAT atypical cadherin 1) • CARD11 (Caspase Recruitment Domain Family Member 11) • BTG2 (BTG Anti-Proliferation Factor 2)
    |
    TP53 mutation • CDKN2A mutation • MUC16 mutation